Key result
Baseline LVEF >30% predicts ~9-fold greater odds of LVEF improvement on sacubitril/valsartan.
Why the study?
Sacubitril/valsartan improves LVEF in heart failure, but whether the magnitude of improvement depends on baseline values remained unclear.
Does baseline LVEF predict the magnitude of LVEF improvement in heart failure patients receiving sacubitril/valsartan?
Observational (n=256)
No
Does baseline LVEF predict the magnitude of LVEF improvement in heart failure patients receiving sacubitril/valsartan?
In patients with heart failure and LVEF ≤ 45% taking sacubitril/valsartan, a baseline LVEF > 30%, female sex, and higher doses are significant predictors of greater LVEF improvement.
Answers are grounded in this paper and cite their sources.
Baseline LVEF >30% was associated with greater S/V-related improvement; leaves open prospective validation for selection.
BACKGROUND: Sacubitril/valsartan (S/V) improve left ventricular ejection fraction (LVEF) in heart failure patients, but the magnitude of improvement may depend on baseline values. METHODS: We analyzed whether baseline LVEF can predict its improvement in patients with LVEF ≤ 45% receiving S/V. Patients were divided into 4 groups (G) according to baseline LVEF (G1: ≤ 20%; G2: 21-30%; G3: 31-40%; G4: 41-45%). RESULTS: We included 256 patients (age 73 ± 12 years; 73% male; 174 ischemic cardiomyopathy [CM], 82 nonischemic CM) and assessed LVEF at S/V initiation and at 6 and 12 months of therapy. Baseline LVEF (%) values (overall 30.9 ± 8.6) were: G1: 17.3 ± 3.3; G2: 27.5 ± 2.4; G3: 35.5 ± 2; G4: 44.4 ± 1. LVEF increased in 62% of patients, reaching 34.3 ± 10.4% and 35.5 ± 11.2% at 6 and 12 months, respectively (p < 0.001). A significantly higher absolute LVEF increase was found in Groups 3 (7.2 ± 4.3) and 4 (4.2 ± 3.05) than in Groups 1 (0.6 ± 1.5) and 2 (3.5 ± 1.5), in women (5.9 ± 4.4 vs. 4.1 ± 4.5; p < 0.001), with high S/V doses (7.4 ± 4.7 vs. 4.3 ± 4.4; p < 0.001), and in nonischemic CM (6.3 ± 4.9 vs. 3.8 ± 4.2; p < 0.001). On multivariate analysis, female sex (OR 2.18; 95% CI [1.06-4.48]; p = 0.034), high dose (OR 3.38; 95% CI [1.10-10.34]; p = 0.033), and baseline LVEF > 30% (OR 8.62; 95% CI [4.69-15.82]; p = 0.001) were significant predictors of LVEF improvement. CONCLUSIONS: LVEF improvement with S/V depends on baseline values, sex, and dose.
No takes yet. Share an insight, caveat, or question.
Campal et al. (2025) conducted an observational in Heart failure (n=256). Sacubitril/valsartan vs. Baseline was evaluated on LVEF improvement at 12 months (predicted by baseline LVEF > 30%) (OR 8.62, 95% CI 4.69-15.82, p=0.001). In patients with heart failure taking sacubitril/valsartan, a baseline LVEF > 30% strongly predicted LVEF improvement at 12 months, alongside female sex and high drug dose.
Synapse has enriched 10 related papers. Consider them for comparative context: